This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Why Clovis Oncology (CLVS) Stock Hit a One-Year Low Today

NEW YORK (TheStreet) -- Clovis Oncology  (CLVS) continued to plunge to a one-year low of $38.48 on Tuesday with another day of double-digit declines following disappointing data from ASCO 2014 with regard to the company's investigational non-small cell lung cancer drug, CO-1686.

The drug, designed to target target T790M-positive mutation, initially showed an estimated median progression-free survival of greater than 12 months. But CEO Pat Mahaffay told analysts over the weekend that a handful of CO-1686 patients needed to be placed on insulin after instances of hyperglycemia. This indicated some glaring safety concerns about CO-1686, and investors seem to not believe that Mahaffay satisfactorily addressed those concerns in an interview with CNBC on Monday.

Furthermore, Citigroup downgraded Clovis to "neutral" from "buy" and slashed its price target to $53 from $109 on Tuesday. The firm notes the company could face increased competition from AstraZeneca's  (AZN) drug AZN9291 because of the abatement of previous concerns about the drug's cardiotoxicity.

Must Read: Clovis' Lung Cancer Bravado Falls Flat With New Diabetes Revelation

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

For more on this story, read TheStreet's Adam Feuerstein's article here. CLVS Price Chart

CLVS Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
CLVS $85.54 -7.10%
AAPL $132.67 1.80%
FB $82.18 0.80%
GOOG $555.09 -1.80%
TSLA $233.87 7.10%

Markets

DOW 18,073.60 -6.54 -0.04%
S&P 500 2,118.33 +0.64 0.03%
NASDAQ 5,084.9490 -7.1360 -0.14%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs